Leadership Overview
Curia has 10 executives leading key functions including strategy, human resources, finance, information technology, research and development, and drug product operations.
Driven by a commitment to advancing pharmaceutical innovation, Curia provides comprehensive products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers, impacting global health outcomes.
Driven by a commitment to advancing pharmaceutical innovation, Curia provides comprehensive products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers, impacting global health outcomes.
Leadership Roles at Curia
Sam Yasine - Chief Executive Officer
Sam Yasine, the Chief Executive Officer at Curia, directs the overarching corporate strategy and operational execution. This leadership role involves guiding the company's expansion and ensuring alignment with its mission to serve pharmaceutical and biopharmaceutical clients. Yasine oversees the integration of research, development, and manufacturing capabilities, driving efficiency and innovation across all divisions. The Chief Executive Officer's focus remains on enhancing Curia's market position and delivering value to stakeholders through robust service offerings. This executive champions the company's commitment to quality and client success in the competitive life sciences sector. Sam Yasine ensures that the organization's resources are optimally deployed to meet evolving industry demands and achieve long-term growth objectives.
Alex Milenkovic - Founder & Chief Executive Officer
Alex Milenkovic, the Founder & Chief Executive Officer at Curia, established the company's foundational vision and continues to shape its strategic direction. This leadership position involves setting the long-term goals for Curia's contract research, development, and manufacturing services. Milenkovic guides the executive team in fostering a culture of scientific excellence and client collaboration. The Founder & Chief Executive Officer's responsibilities include overseeing major strategic initiatives and ensuring the company's sustained growth within the pharmaceutical and biopharmaceutical industries. Alex Milenkovic's influence is critical in maintaining the company's innovative edge and its reputation for delivering high-quality solutions from R&D through commercial manufacturing. This executive drives the company's commitment to advancing drug development for global health.
Gerald Auer - Group Chief Financial Officer
Gerald Auer, the Group Chief Financial Officer at Curia, directs all financial operations and strategic financial planning for the organization. This executive manages corporate finance, accounting, treasury, and investor relations, ensuring fiscal health and driving profitable growth. Auer oversees the financial aspects of Curia's global R&D and manufacturing services, providing critical insights for strategic decision-making. The Group Chief Financial Officer's responsibilities include optimizing capital allocation, managing financial risk, and ensuring compliance with all regulatory requirements across different markets. Gerald Auer plays a key role in supporting the company's expansion initiatives and maintaining strong relationships with financial institutions and stakeholders. This executive ensures financial integrity and supports the company's mission to deliver value to pharmaceutical and biopharmaceutical customers.
James Grabowski - President, Research & Development
James Grabowski, the President, Research & Development at Curia, spearheads the company's scientific innovation and early-stage drug discovery services. This executive directs all research activities, guiding teams in exploring novel therapeutic targets and developing cutting-edge methodologies for pharmaceutical and biopharmaceutical clients. Grabowski oversees the integration of advanced research technologies and ensures the quality and integrity of scientific data generated. The President, Research & Development's focus is on advancing the pipeline of client projects from conceptualization through preclinical development. James Grabowski plays a critical role in fostering a collaborative research environment and translating scientific insights into tangible progress for drug development, reinforcing Curia's position as a leader in contract research.
Valentina Makovkina - President
Valentina Makovkina, the President at Curia, drives strategic initiatives and operational excellence across key business segments. This executive focuses on enhancing the company's service offerings in pharmaceutical and biopharmaceutical development and manufacturing. Makovkina oversees the execution of complex projects, ensuring alignment with client objectives and regulatory standards. The President's responsibilities include fostering cross-functional collaboration and optimizing resource allocation to maximize efficiency and client satisfaction. Valentina Makovkina plays a vital role in strengthening Curia's market presence and expanding its capabilities in providing end-to-end solutions from research through commercialization. This leadership position is instrumental in achieving the company's growth targets and reinforcing its reputation for reliability and innovation.
Scott Wagner - President, Drug Product
Scott Wagner, the President, Drug Product at Curia, leads the company's comprehensive drug product development and manufacturing operations. This executive oversees the formulation, manufacturing, and packaging of pharmaceutical products, ensuring adherence to stringent quality and regulatory requirements. Wagner directs teams responsible for scaling up production from clinical trial materials to commercial launch volumes. The President, Drug Product's focus is on optimizing manufacturing processes, enhancing supply chain efficiency, and ensuring the timely delivery of high-quality drug products to clients worldwide. Scott Wagner plays a crucial role in supporting pharmaceutical and biopharmaceutical companies in bringing their therapies to market, reinforcing Curia's end-to-end service capabilities.
Kourtney Forster - President
Kourtney Forster, the President at Curia, directs strategic operations and business development initiatives within the organization. This executive focuses on expanding Curia's service portfolio and strengthening client relationships across the pharmaceutical and biopharmaceutical sectors. Forster oversees the implementation of key growth strategies and ensures operational alignment with market demands. The President's responsibilities include identifying new opportunities for innovation and enhancing the company's competitive positioning. Kourtney Forster plays a significant role in driving the company's mission to provide integrated solutions from research and development through commercial manufacturing, contributing to the successful advancement of client projects and overall business expansion.
Ronald Aungst - President, Drug Product
Ronald Aungst, the President, Drug Product at Curia, oversees the strategic direction and operational execution of drug product manufacturing services. This executive manages the end-to-end processes involved in producing finished pharmaceutical dosage forms, ensuring compliance with global regulatory standards. Aungst drives initiatives to enhance manufacturing efficiency, implement advanced technologies, and maintain the highest levels of product quality. The President, Drug Product's role is critical in supporting pharmaceutical and biopharmaceutical clients through the complex journey of drug commercialization. Ronald Aungst ensures that Curia's drug product capabilities effectively meet market needs, contributing significantly to the company's mission of advancing healthcare solutions from development to market.
Joseph Sangregorio - Chief Human Resources Officer
Joseph Sangregorio, the Chief Human Resources Officer at Curia, architects the global talent strategy and organizational development initiatives. This executive oversees all human capital functions, including recruitment, employee engagement, compensation, and benefits, ensuring a robust workforce to support Curia's complex operations. Sangregorio drives programs that foster a high-performance culture and promote professional growth across the organization's R&D and manufacturing divisions. The Chief Human Resources Officer's role is pivotal in aligning human resources policies with the company's strategic objectives, particularly in attracting and retaining specialized scientific and technical talent. Joseph Sangregorio ensures that Curia's workforce is equipped to meet the demands of pharmaceutical and biopharmaceutical clients, supporting seamless service delivery from early-stage research to commercial production.
Gregory Kuzma - Senior Vice President, Chief Information Officer
Gregory Kuzma, the Senior Vice President, Chief Information Officer at Curia, leads the company's technology strategy and digital transformation efforts. This executive oversees the development and implementation of IT infrastructure, cybersecurity measures, and data management systems essential for Curia's R&D and manufacturing operations. Kuzma ensures that technology solutions enhance operational efficiency, support scientific innovation, and safeguard sensitive client data. The Senior Vice President, Chief Information Officer's role involves aligning IT capabilities with business objectives, enabling seamless collaboration across global teams and supporting the company's service delivery to pharmaceutical and biopharmaceutical clients. Gregory Kuzma drives the adoption of advanced technologies to optimize workflows and maintain a competitive advantage in the life sciences sector.
Explore Leadership Teams in Manufacturing
Bristol-Myers Squibb operates as a global biopharmaceutical organization dedicated to discovering, developing, and manufacturing prescription medications that address serious patient needs across multiple therapeutic domains. The company's scientific expertise spans oncology, cardiovascular disease, immunoscience, and virology, with particular depth in treating complex conditions including HIV and cancer. Through sustained investment in research and development, the organization has built a comprehensive medication portfolio that combines innovative cancer immunotherapies, anticoagulant therapies, and treatments for chronic viral infections. The company's operational footprint extends across major markets worldwide, enabling efficient distribution and patient access to its therapeutic solutions. Bristol-Myers Squibb pursues a collaborative approach to medical innovation, actively engaging in research partnerships and strategic alliances that accelerate the development of new treatment options. This commitment to external collaboration complements the organization's internal capabilities, creating a dynamic environment where scientific breakthroughs can translate into meaningful therapeutic advances. Bristol-Myers Squibb's medication portfolio reflects decades of pharmaceutical expertise and a strategic focus on disease areas where unmet medical needs remain significant.
Company Leadership BT
DG
KK
Founded in 2005, Headquartered in Tokyo, Daiichi Sankyo is a global pharmaceutical company that develops and provides innovative new and generic medicines, as well as advanced drug discovery and delivery methods, serving patients in over 30 countries.
Company Leadership JN
KI
CB
HS
Zai Lab functions as a bio-pharmaceutical and drug discovery company with a focus in oncology and autoimmune diseases. The company was established in 2014 and is headquartered out of Shanghai, China.
Company Leadership KL
HR
DL
JS
Amicus Therapeutics is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases.
Company Leadership
CA
SH
ST
Frequently Asked Questions Regarding Curia Top Executives and Leadership Team
